Page last updated: 2024-09-04

canertinib dihydrochloride and Thrombocytopenia

canertinib dihydrochloride has been researched along with Thrombocytopenia in 2 studies

Research

Studies (2)

Timeframe	Studies, this research(%)	All Research%
pre-1990	0 (0.00)	18.7374
1990's	1 (50.00)	18.2507
2000's	1 (50.00)	29.6817
2010's	0 (0.00)	24.3611
2020's	0 (0.00)	2.80

Authors

Authors	Studies
Fine, H; Hess, K; Jaeckle, K; Kunschner, LJ; Kyritsis, AP; Yung, WK	1
Bowling, MK; Donehower, RC; Grochow, LB; Long, GS; Noe, DA; Rowinsky, EK; Sartorius, SE	1

Trials

2 trial(s) available for canertinib dihydrochloride and Thrombocytopenia

Article	Year
CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980. Cancer investigation, 2002, Volume: 20, Issue:7-8 Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome	2002
Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent. Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3 Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia	1997

Article

Year

CI-980 for the treatment of recurrent or progressive malignant gliomas: national central nervous system consortium phase I-II evaluation of CI-980.

Cancer investigation, 2002, Volume: 20, Issue:7-8

Topics: Adult; Aged; Antineoplastic Agents; Brain Neoplasms; Carbamates; Disease-Free Survival; Female; Glioma; Humans; Infusions, Intravenous; Male; Maximum Tolerated Dose; Middle Aged; Neoplasm Recurrence, Local; Pyrazines; Pyridines; Survival Rate; Thrombocytopenia; Treatment Outcome

2002

Phase I and pharmacological study of CI-980, a novel synthetic antimicrotubule agent.

Clinical cancer research : an official journal of the American Association for Cancer Research, 1997, Volume: 3, Issue:3

Topics: Adult; Aged; Antineoplastic Agents; Carbamates; Central Nervous System Diseases; Dose-Response Relationship, Drug; Drug Administration Schedule; Female; Follow-Up Studies; Humans; Infusions, Intravenous; Male; Metabolic Clearance Rate; Middle Aged; Neoplasms; Neutropenia; Pyrazines; Pyridines; Thrombocytopenia

1997